RxDoctor Payments Data

Prateek Sharma, MD

Interventional Cardiology · Chicago, ILNPI 1679831820

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (49.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Abbott at 36.2% of the total. Reporting peaked in 2023 at $3,802 and has fallen 58.2% since, to $1,590 in 2025.

$10,955in general payments, 2019–2025

Across 129 payments — averaging $84.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Medtronic$2K
  • Penumbra, Inc.$1K
  • Inari Medical, Inc.$1K
  • Shockwave Medical, Inc$620
  • Abiomed$476
  • plus $1K from 14 others
$11,093in research payments, 2019–2025

Across 8 payments — averaging $1386.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ironwood Pharmaceuticals, Inc$11K
  • Abbott$93

What the payments were for

  • Travel & lodging$5,41249%
  • Food & beverage$5,44450%
  • Education$991%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,955 in reported general payments places this provider in the 60th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois →

Medicare billing

Part B allowed, 2024
$99,403
Medicare patients
699
Services billed
1,219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Rosuvastatin Calcium61$535
ClopidogrelClopidogrel Bisulfate20$224
Metoprolol Succinate25$164
Lisinopril15$145
Isosorbide Mononitrate ErIsosorbide Mononitrate19$138
Carvedilol20$130
Amlodipine Besylate33$117
Atorvastatin Calcium20$93
Spironolactone18$30

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Chicago

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →